Search

You searched for "elective"

1998 results found

Théa Pharmaceuticals are excited to be attending RCOphth Congress 2023 with two innovative new products.

22 May 2023 | Research & Development, Awards, Conferences & Anniversaries
This year Théa will also have two stands – one right by the registration desk which will be focused on product sampling and a larger stand inside the main exhibition hall which will showcase the wider product range.

Sight Sciences Glaucoma Fellows Academy, Birmingham

20 October 2023 | Research & Development, Recruitment & Personnel, Awards, Conferences & Anniversaries
Saturday 7 October saw Sight Sciences hold their inaugural UK Glaucoma Fellows Academy training day.

Haag-Streit UK look forward to exhibiting at 100% Ophthalmology 2024

19 January 2024 | Awards, Conferences & Anniversaries, Company Profiles
Haag-Streit UK (HS-UK), the leading manufacturer and distributor of gold-standard diagnostic and surgical devices and instruments for ophthalmologists, optometrists, and orthoptists, is pleased to announce it will be exhibiting at 100% Ophthalmology in February 2024.

Sight Sciences Celebrates 150th Certified UK OMNI Surgeon

13 June 2025 | Awards, Conferences & Anniversaries, Company Profiles, Research & Development
Sight Sciences is proud to announce that 150 ophthalmic surgeons in the United Kingdom are now certified to use the OMNI® Surgical System. This milestone was marked by the recent certification of Ms. Diana Urbaneja, Consultant Ophthalmic Surgeon at University...

Aspiration of anteriorly migrated dexamethasone implant using an 18G intravenous cannula

4 December 2025 | | EYE - Cornea, EYE - Vitreo-Retinal
Intravitreal dexamethasone (Ozurdex 0.7mg) is a biodegradable, sustained-release implant used to manage diabetic macular oedema, macular oedema secondary to retinal vein occlusion, and non-infectious posterior uveitis due to its anti-inflammatory effects and VEGF suppression [1]. While effective, the implant may...
Ophthalmologica journal front cover image.

AI-Based devices in national screening programmes: barriers and challenges

4 December 2025 | | EYE - Vitreo-Retinal
Diabetic retinopathy (DR) may have long-term complications and is recorded as a leading cause of blindness. National DR screening programmes have effectively reduced severe visual loss by timely detection and subsequent treatment of sight-threatening proliferative DR and diabetic macular oedema....

MacuMira and Keeler announce strategic partnership to expand dry AMD therapy

11 December 2025 | Contracts & Distributors, Research & Development
Keeler, a global leader in ophthalmic innovation with more than a century of heritage, and MacuMira Medical Devices Inc, a pioneering Canadian company, has announced a strategic partnership. Under the agreement, Keeler will manufacture the MacuMira device and lead its...

Marsha de Cordova MP presented with an Honorary Fellowship of The College of Optometrists

6 February 2026 | optometry
This week, The College of Optometrists formally presented Marsha de Cordova MP with an Honorary Fellowship at the College’s headquarters in London. Marsha de Cordova is the Labour MP for Battersea, a former Lambeth Councillor and a longstanding champion of...

ABDO awards presented at graduation and prize giving ceremony

16 June 2025 | achievements, awards, news, opticians, optometry
The president of the Association of British Dispensing Opticians (ABDO), Kevin Gutsell, presented six special awards at the Association's recent graduation and prize giving ceremony held at Canterbury Cathedral. ABDO Life Membership was awarded to Fiona Anderson, SMC (Tech), BSc...

Traumatic optic neuropathy

1 October 2021 | | EYE - Orbit, EYE - Neuro-ophthalmology, EYE - General
In neuro-ophthalmology we get asked a lot about management of patients who suffered significant trauma and presented with loss of vision secondary to presumed traumatic optic neuropathy (TON). TON happens usually in the context of significant craniofacial trauma. The incidence...

PACK-crosslinking for infectious keratitis

1 October 2015 | | EYE - Cornea
Corneal cross-linking with riboflavin and UV-A light (CXL) is a technology that has been initially developed to treat corneal ectatic disorders [1]. Its effect in stabilising diseases such as keratoconus was reported in numerous trials with excellent long-term outcomes and...

Pharma chameleon

3 April 2024 | | EYE - General
One morning in September ’95, about a month into my first house job on the South Coast of England, I emerged from the ridiculously early ward round on the coronary care unit feeling a bit dazed and therefore headed off...